Funder: Alnylam Pharmaceuticals
Due Dates: Rolling (submit ≥45 days before project start)
Funding Amounts: No fixed maximum; funding determined by project scope and mutual agreement.
Summary: Supports joint projects between Alnylam and external organizations to advance science, healthcare, and education in rare diseases via shared expertise and active partnership.
Key Information: Proposals must align with Alnylam’s areas of interest (e.g., ATTR amyloidosis, AHP, PH1) and require organizational eligibility and proof of tax status for funding.